Milestone Pharmaceuticals Files 8-K on Financials
Ticker: MIST · Form: 8-K · Filed: Aug 8, 2024 · CIK: 1408443
Sentiment: neutral
Topics: financial-condition, operations, filing
TL;DR
Milestone Pharma dropped an 8-K on Aug 8th covering financials and operations.
AI Summary
On August 8, 2024, Milestone Pharmaceuticals Inc. filed an 8-K report. The filing pertains to the company's results of operations and financial condition, as well as financial statements and exhibits. The report was filed in the United States and relates to the company's principal executive offices located in Montreal, Quebec.
Why It Matters
This 8-K filing provides crucial updates on Milestone Pharmaceuticals' financial health and operational results, which are important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Milestone Pharmaceuticals Inc. (company) — Registrant
- August 8, 2024 (date) — Date of earliest event reported
- Montreal, Quebec (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing by Milestone Pharmaceuticals Inc.?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 8, 2024.
Where are Milestone Pharmaceuticals Inc.'s principal executive offices located?
Milestone Pharmaceuticals Inc.'s principal executive offices are located at 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montréal, Québec, CA H4M 2X6.
What is the SIC code for Milestone Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Milestone Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the Commission File Number for Milestone Pharmaceuticals Inc.?
The Commission File Number for Milestone Pharmaceuticals Inc. is 001-38899.
Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-08-08 16:28:42
Filing Documents
- tm2421158d1_8k.htm (8-K) — 26KB
- tm2421158d1_ex99-1.htm (EX-99.1) — 95KB
- tm2421158d1_ex99-1img001.jpg (GRAPHIC) — 6KB
- 0001104659-24-087301.txt ( ) — 315KB
- mist-20240808.xsd (EX-101.SCH) — 3KB
- mist-20240808_lab.xml (EX-101.LAB) — 33KB
- mist-20240808_pre.xml (EX-101.PRE) — 22KB
- tm2421158d1_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On August 8, 2024, Milestone Pharmaceuticals Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2024, which also provided a clinical and corporate update. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference. Item 9.01. Financial (d) Exhibits. Exhibit No. Description 99.1 Press Release dated August 8, 2024 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MILESTONE PHARMACEUTICALS INC. By: /s/Amit Hasija Amit Hasija Chief Financial Officer Dated: August 8, 2024